about
Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity.Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?Searching for the Pareto frontier in multi-objective protein design.Immunity to CRISPR Cas9 and Cas12a therapeutics.Mining ancient proteins for next-generation drugs.DisruPPI: structure-based computational redesign algorithm for protein binding disruption.
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Design and engineering of deimmunized biotherapeutics.
@en
type
label
Design and engineering of deimmunized biotherapeutics.
@en
prefLabel
Design and engineering of deimmunized biotherapeutics.
@en
P2860
P1476
Design and engineering of deimmunized biotherapeutics
@en
P2093
Chris Bailey-Kellogg
P2860
P356
10.1016/J.SBI.2016.06.003
P577
2016-06-17T00:00:00Z